does semaglutide cause blurry vision Northeast Ohio woman reports loss from taking Ozempic Wegovy Vision Loss Lawsuit [2026

Recommendation (Evidence Strength: Grade C) Systemic (oral) long-term glucocorticoid administration should not be offered

3163 ( IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation) is active and exclusively for claims involving partial blindness/vision loss caused by GLP-1 use

People taking gabapentin should pay attention to any changes in their weight, especially if they are also taking a medication like semaglutide, which is used to help with weight loss

Same-day appointments are available most days

Some aspects of the research appear promising, while others remain unproven: What appears promising so far: Reduced substance-seeking behavior observed in animal models Anecdotal and observational reports of decreased cravings in some individuals Growing scientific interest in shared reward pathways between appetite and addiction What remains unproven or unclear: Whether observed effects lead to sustained recovery outcomes How GLP-1s affect the psychological and social dimensions of addiction Whether benefits, if present, are consistent across substances or populations Differences in study design also limit interpretation: Animal trials do not reliably predict human outcomes Observational data cannot establish causation Controlled human trials remain small, limited, and inconsistent Safety considerations are equally important and must be weighed carefully: Common side effects include nausea, appetite suppression, and gastrointestinal distress Changes in appetite or weight may interact with existing mental health symptoms For individuals with eating disorders, appetite-suppressing effects may pose particular risks Given these uncertainties, GLP-1 medications should not replace evidence-based addiction treatments

Factors independent of glycaemic and weight loss effects have also been suggested to affect the cardiovascular protective effects of GLP-1RAs